Johnson and Johnson

COVID-19 Vaccine Outcomes in Dermatomyositis Patients

A recent study evaluated the safety and efficacy of the Moderna, Pfizer, and Johnson & Johnson COVID-19 vaccines in dermatomyositis (DM) patients compared to non-DM patients at 1, 30, and 60 days post-vaccination. At 60 days post-vaccination, the DM group was observed to be at greater risk for adverse events of special interest compared to controls, albeit very small (absolute risk was .6%). No differences were observed for breakthrough infection or all-cause hospitalization at 60 days post-vaccination.

Read More »

Adenovirus Vaccines and Blood Clots

New research suggests how COVID-19 adenovirus vaccines may lead to extremely rare cases of thrombosis with thrombocytopenia syndrome (TTS), an autoimmune response which can lead to fatal blood clots. Thrombosis with thrombocytopenia was verified by the WHO as a possible adverse event to AstraZeneca and Johnson & Johnson COVID-19 vaccines earlier this year, following the first but rarely after the second dose.

Read More »
Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.

By adding your phone number, you agree to receive text message updates. Msg & data rates may apply.